MULTI BAGGER ALERTS

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Inc (OTCMKTS:PMCB) At The Forefront Of Diabetes Treatment








Globally, the race is on for more effective treatments of diabetes. A new report by Visiongain predicts the world market for diabetes medications will reach $55.3B in 2017. The antidiabetic medicines industry generated $35.6B in 2012, and its revenues will show strong growth to 2023. Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech Inc (OTCMKTS:PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of millions of these patients.
PharmaCyte recently learned from the U.S. Patent and Trademark Office (USPTO) that it now has 20 years of patent protection in the United States for the “Melligen” cells that are a part of the company’s therapy for Type 1 and insulin-dependent Type 2 diabetes. Patent protection in the European Union has already been granted. The patent has been validated in France, Switzerland, Great Britain, Ireland, Germany, Spain, Denmark, Italy and the Netherlands with similar claim scope of the allowed claims by the USPTO. The timing is perfect because the same research that laid out the dramatic rise in the numbers of people affected by diabetes, also found that the global cost of diabetes has ballooned to $825-billion per year.
This is a tremendous opportunity for PharmaCyte. This small cap is making strides where other bigger players are seeing setbacks. Pharma giant Sanofi has spent $245 million on a priority review voucher to beat Novo Nordisk to market with a diabetes med pairing a basal insulin with a GLP-1. Novo’s drug, Xultophy, pairs its recently approved, longer-acting basal insulin Tresiba with its GLP-1 blockbuster Victoza. The FDA is expected to make a decision next month on Xultophy while Sanofi’s Lantus-plus-lixisenatide combo has been pushed off till November at the least. With PBCB trading under $.05 a share, this is quite a compelling opportunity for investors.

PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as an “artificial pancreas” for purposes of insulin production.
The Melligen cells are human cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body. PharmaCyte has the exclusive worldwide license from the University of Technology Sydney (UTS) to use these cells to develop a therapy for Type 1 and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Box technology to function as an “artificial pancreas” for purposes of insulin production. PMCB CEO Kenneth Waggoner said:
“We are pleased that the USPTO has granted patent protection of the Melligen cells. It protects this unique cell line and enables us to move forward with our efforts to develop an artificial pancreas for those who suffer from diabetes. If we are successful in our efforts, it will bring to fruition the many years of research that have been conducted by Professor Ann Simpson and her colleagues at UTS in developing these remarkable cells. For the millions of people around the globe who suffer from diabetes – a disease of epidemic proportions – our therapy could relieve them of the onerous daily requirements of insulin administration and dietary restrictions and offer a life free from the life threatening complications associated with this disease.”
Currently trading with a market cap of $33 million, PMCB has a history of explosive moves. Besides the treatment of diabetes, PMCB is finalizing the design of its upcoming Phase 2b clinical trial for the treatment of prostate cancer. Once this trial gets underway, we believe shares of PMCB will be off and running. Worth noting is that PMCB has $1.9 million in cash and NO debt. This certainly differentiates PMCB from other small cap biotech names. We will be updating our subscribers as soon as we know more. For the latest updates on PMCB, sign up below!
Disclosure: We have no position in PMCB and have not been compensated for this article.